Natixis Advisors, L.P. Grifols Sa Transaction History

Natixis Advisors, L.P.

$54.1 Billion
Q1 2025

A detailed history of Natixis Advisors, L.P. transactions in Grifols Sa stock. As of the latest transaction made, Natixis Advisors, L.P. holds 212,585 shares of GRFS stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

212,585

Previous 176,720 20.29%

Holding current value

$1.85 Million

Previous $1.32 Million 14.9%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$6.62 - $8.71 $237,426 - $312,384	35,865 Added 20.29%	212,585 $1.51 Million
Q4 2024 Feb 10, 2025	SELL	$6.99 - $9.55 $272,239 - $371,943	-38,947 Reduced 18.06%	176,720 $1.32 Million
Q3 2024 Nov 06, 2024	BUY	$6.28 - $9.38 $386,935 - $577,939	61,614 Added 40.0%	215,667 $1.92 Million
Q2 2024 Aug 01, 2024	BUY	$6.27 - $7.7 $518,673 - $636,967	82,723 Added 115.97%	154,053 $971,000
Q1 2024 Apr 25, 2024	SELL	$5.47 - $11.38 $513,605 - $1.07 Million	-93,895 Reduced 56.83%	71,330 $476,000
Q4 2023 Feb 06, 2024	SELL	$7.71 - $11.56 $26,707 - $40,043	-3,464 Reduced 2.05%	165,225 $1.91 Million
Q3 2023 Nov 13, 2023	SELL	$8.91 - $10.91 $19,183 - $23,489	-2,153 Reduced 1.26%	168,689 $1.54 Million
Q2 2023 Aug 15, 2023	BUY	$7.14 - $9.29 $17,014 - $22,138	2,383 Added 1.41%	170,842 $1.57 Million
Q1 2023 May 11, 2023	SELL	$6.65 - $10.69 $52,249 - $83,991	-7,857 Reduced 4.46%	168,459 $1.24 Million
Q4 2022 Jan 27, 2023	BUY	$5.96 - $8.53 $1,823 - $2,610	306 Added 0.17%	176,316 $1.5 Million
Q3 2022 Nov 14, 2022	SELL	$5.95 - $14.3 $826,080 - $1.99 Million	-138,837 Reduced 44.1%	176,010 $1.08 Million
Q2 2022 Aug 12, 2022	BUY	$10.6 - $13.28 $221,444 - $277,432	20,891 Added 7.11%	314,847 $3.74 Million
Q1 2022 May 12, 2022	BUY	$10.37 - $12.73 $1.18 Million - $1.45 Million	113,512 Added 62.91%	293,956 $3.43 Million
Q4 2021 Feb 08, 2022	BUY	$10.21 - $15.27 $66,977 - $100,171	6,560 Added 3.77%	180,444 $2.03 Million
Q3 2021 Nov 15, 2021	SELL	$14.07 - $17.3 $792,464 - $974,387	-56,323 Reduced 24.47%	173,884 $2.54 Million
Q2 2021 Aug 12, 2021	BUY	$16.62 - $18.94 $2.08 Million - $2.36 Million	124,865 Added 118.53%	230,207 $3.99 Million
Q1 2021 May 05, 2021	SELL	$15.15 - $19.78 $875,291 - $1.14 Million	-57,775 Reduced 35.42%	105,342 $1.82 Million
Q4 2020 Feb 12, 2021	BUY	$16.86 - $19.67 $1.51 Million - $1.76 Million	89,274 Added 120.9%	163,117 $3.01 Million
Q3 2020 Nov 12, 2020	BUY	$15.4 - $20.16 $145,945 - $191,056	9,477 Added 14.72%	73,843 $1.28 Million
Q2 2020 Aug 11, 2020	BUY	$18.24 - $21.45 $72,029 - $84,706	3,949 Added 6.54%	64,366 $1.17 Million
Q1 2020 Apr 27, 2020	BUY	$16.28 - $25.63 $97 - $153	6 Added 0.01%	60,417 $1.22 Million
Q4 2019 Feb 10, 2020	SELL	$19.57 - $23.52 $719,804 - $865,089	-36,781 Reduced 37.84%	60,411 $1.41 Million
Q3 2019 Nov 12, 2019	BUY	$19.85 - $22.76 $215,868 - $247,515	10,875 Added 12.6%	97,192 $1.95 Million
Q2 2019 Aug 12, 2019	SELL	$17.59 - $21.1 $4,503 - $5,401	-256 Reduced 0.3%	86,317 $1.82 Million
Q1 2019 May 15, 2019	BUY	$18.01 - $20.11 $59,703 - $66,664	3,315 Added 3.98%	86,573 $1.74 Million
Q4 2018 Feb 13, 2019	SELL	$17.44 - $21.53 $13.3 Million - $16.5 Million	-764,643 Reduced 90.18%	83,258 $1.53 Million
Q3 2018 Nov 13, 2018	BUY	$19.97 - $21.96 $1.14 Million - $1.25 Million	56,967 Added 7.2%	847,901 $18.1 Million
Q2 2018 Aug 14, 2018	BUY	$20.16 - $24.68 $701,406 - $858,666	34,792 Added 4.6%	790,934 $0
Q1 2018 May 10, 2018	BUY	$20.31 - $24.95 $1.54 Million - $1.89 Million	75,861 Added 11.15%	756,142 $16 Million
Q4 2017 Feb 14, 2018	BUY	$20.99 - $23.89 $556,633 - $633,538	26,519 Added 4.06%	680,281 $15.6 Million
Q3 2017 Nov 14, 2017	BUY	$20.07 - $21.89 $13.1 Million - $14.3 Million	653,762	653,762 $14.3 Million

Others Institutions Holding GRFS

# of Institutions

166

Shares Held

153M

Call Options Held

76.5K

Put Options Held

106K

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.92B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Grifols Sa Transaction History